Resources / events
BioDuro-Sundia Services & Capabilities Overview
BioDuro-Sundia understands the value our clients place on partnering with the right CRO/CDMO. We work as true partners throughout the discovery, development and manufacturing process, to provide a new and reliable source of efficiencies, ideas and innovation, while ensuring an exceptional customer experience
BioDuro-Sundia develops robust and cost-effective chemistry processes from early discovery to kilogram quantity process chemistry. Learn more about our capabilities by downloading our fact sheet below.
From early discovery to IND-enabling studies, BioDuro provides world-class quality data for in vitro ADME and in vivo PK studies. Learn more about our capabilities by downloading our fact sheet below.
Ames Mutagenicity Test
Screen compounds early in the drug discovery process to identify compounds with mutagenic potential. Learn more about our capabilities by downloading our fact sheet below.
Recombinant Protein Production
At BioDuro we offer recombinant protein expression in bacterial, insect, and mammalian systems. Learn more about our capabilities by downloading our fact sheet below.
BioDuro-Sundia provides preclinical solutions for anti-cancer drug discovery in 2D and 3D cellular models and animal tumor models. Learn more about our capabilities by downloading our fact sheet below.
hTME-3DX Screen and Verify™
BioDuro-Sundia offers the first drug screening platform to combine humanized 3D tumor models in vitro and follow-on in vivo PDX capability, matched to same primary patient sample. Learn more about hTME-3DX Screen and Verify™ by downloading our fact sheet below.
Human Tumor Biobank
Through the acquisition of Molecular Response, BioDuro-Sundia’s oncology platform comprises the world’s largest viable tumor collection of over 100,000 biospecimens. Learn more about our capabilities by downloading the fact sheet below.
Our Pharmacology team provides comprehensive in vivo assays and animal models for studying efficacy and mechanism of action of drug candidates.
Immunology and Inflammatory Disease
BioDuro-Sundia Pharmacology provides in vitro assays and disease models for inflammatory and autoimmune diseases to help our clients evaluate the efficacy of their compounds.
BioDuro-Sundia Analytical Development provides necessary data for the development process from discovery candidates to clinical trial materials. Learn more about our capabilities by downloading our fact sheet below.
Drug Product Manufacturing
BioDuro-Sundia offers cGMP manufacturing services with quality, efficiency and timeliness of delivery in mind. Learn more about our capabilities by downloading our fact sheet below.
Amorphous Solid Dispersions
BioDuro-Sundia has extensive experience and a range of bioavailability enhancement solutions for poorly soluble compounds. Learn more about our capabilities by downloading our fact sheet below.
LOCUS: Queryable Database of Cancer Genomics and Pharmacologic Response Enables Rapid Selection of Preclinical Tumor Models
LOCUS: Queryable Database of Cancer Genomics and Pharmacologic Response Enables Rapid Selection of Preclinical Tumor Models” was presented at AACR 2019 by Dr. Tommy Broudy.
Enteric Solid Dosage Formulation for Physiologically Active Proteins and Peptides
Poster on study aimed at developing an enteric solid dosage formulation, allowing oral administration of a physiologically active protein.
Effect of Additives on Preparation of Posaconazole Nano-Suspensions
The purpose of this study was to evaluate additives that can be used to prepare stable Posaconazole nano-suspensions as a precursor to oral dosage forms containing nanoparticles.
Effect of Nozzle Mechanism and Spray Dried Dispersion Parameters on Final Dissolution of Spray Dried Tablets
Scientific poster investigating the effect of change from a pressure nozzle to a two fluid nozzle on final quality attributes of a spray dried formulation of tablets and to determine the potential cause of quality attribute changes
Ex Vivo Three-dimensional Tumor Growth Assay: 3DX-TGA
Poster on the establishment, serial propagation and molecular characterization of 300+ ex vivo 3D (3DX) models spanning 16 tumor indications, as a practical alternative to PDX models. Presented by Brett Hall, Ph. D., at AACR 2017.
hTME-3DX Screen and Verify™ is based on the proprietary primary tumor bank and 3D drug screening platform that was developed by Molecular Response, through a large body of academic and commercial research over the past decade, as well as, internal expertise in ex vivo cell cultures and human tumor sample preservation.
Novel Gastro-Retentive Formulation for Methyldopa Using Hot Melt Extrusion (HME) Technology
Poster on formulation of a novel gastro-retentive sustained release oral formulation for methyldopa to treat Type I diabetes, presented by Ruchit Trivedi, Ph. D., at AAPS 2016.
Reducing Residual Crystallinity in Hot Melt Extrusion (HME) Formulations Optimization
Poster on improvement of existing hot melt extrusion formulations showing recrystallization due to moisture absorption, and high percentage impurities, presented at AAPS 2016.
Microevaporative Dispersion as a Predictor of Dissolution Performance of Amorphous Dosage Forms
Poster on microevaporative dispersion as an early predictor of dissolution performance of amorphous dosage forms.
Multiparticulate Drug Delivery System for Physiologically Active Proteins and Peptides
Poster on the development of a multiparticulate drug delivery system for physiologically active proteins that can be administered as an oral suspension, or through nasogastric tubes.
Rapid Development and Scale-up of Solubilized Dosage Forms
Hear from Ruchit Trivedi Ph.D., Associate Director of Formulation at BioDuro-Sundia on strategies for developing poorly soluble drugs. He discusses the advantages of amorphous materials and solubilization approaches using spray drying and hot melt extrusion.
Enabled Formulations Bridging Discovery and Development
Hear BioDuro-Sundia’s CSO of Global CMC Solutions, Blair West, Ph.D., present on challenges and opportunities in late discovery and early development formulation and how a multidisciplinary approach that integrates areas such as formulation development and DMPK can accelerate the development pathway.
Paving the Road to the Clinic: Translational Oncology & Immuno-oncology Tumor Models
Hear from Tommy Broudy, Executive Vice President, Translational Sciences & Strategy on clinically relevant models for anti-cancer drug discovery. He discusses in vitro and in vivo models, the importance of the tumor microenvironment, and preclinical immunoprofiling of patient populations.
Integrated Drug Development at BioDuro
Formulation & Drug Delivery Congress USA
March 18-19th, 2019
San Diego, CA
American Association of Cancer Research Annual Meeting
March 29th-April 3rd, 2019
CHI Drug Discovery Chemistry
April 9-11th, 2019
San Diego, CA
CPhI N. America
April 30-May 2nd, 2019